VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on February 24, 2016, covering events that occurred on February 17 and February 19, 2016. The company, incorporated in Nevada, reported unregistered sales of equity securities and warrant exchange agreements.
Key Financial Metrics and Capital Structure
The filing details specific capital raising and restructuring activities rather than operational financial performance metrics such as revenue or profit.
- Cash Proceeds: The company received $200,000 in cash from a private placement transaction.
- Use of Proceeds: Funds are designated for general corporate purposes.
- Capital Structure Update: Following the transactions, the total Common Stock and Common Stock equivalents outstanding stand at 9,092,878 shares.
Material Changes and Transactions
Two primary transactions were executed during the reporting period:
- Series B Preferred Unit Sale: On February 17, 2016, the company sold 28,571 shares of Series B 10% Convertible Preferred Stock and five-year warrants to purchase 28,571 shares of common stock at an exercise price of $7.00 per share to an accredited investor.
- Warrant Exchange Agreements: Between February 17 and February 19, 2016, the company entered into agreements with holders of outstanding warrants to purchase 173,648 shares of common stock. These holders agreed to cancel the warrants in exchange for 130,240 shares of unregistered common stock.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard disclosure that the securities were sold in reliance on exemptions under Section 4(2) and/or 3(a)(9) of the Securities Act and Rule 506 of Regulation D. The filing confirms that all recipients represented themselves as accredited investors.
Investor Verification Checklist
- Verify the dilution impact of the 130,240 shares issued in the warrant exchange and the 28,571 new preferred shares.
- Confirm the conversion ratios for Series A (1:1.5), Series B (1:1), and Series C (1:1) preferred stock to assess total potential common share count.
- Review the terms of the five-year warrants issued in the private placement, specifically the $7.00 exercise price relative to current market conditions.
- Check subsequent filings to determine how the $200,000 in proceeds has been utilized for general corporate purposes.